Remove

	Application Number		09902224	
	Filing Date		2001-07-10	
NFORMATION DISCLOSURE	First Named Inventor Shiny		nya TSUKIZAKI	
Not for submission under 37 CFR 1.99)	Art Unit		2628	
notion submission and or or or it may	Examiner Name	Jacint	ta M. CRAWFORD	
	Attorney Docket Number		SCED 18.553	

U.S.PATENTS

						0.3.1	AIENIS			110111010	
		Kind Code ¹			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear						
	1										
If you wisl	h to ac	id a	dditional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	_
				U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove	
Examiner Initial*			Name of Pate of cited Docu	entee or Applicant ment	Rele	s,Columns,Lines where vant Passages or Relev es Appear					
	1										
If you wish	h to ac	id a	idditional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ade	d butto	n. Add	
					FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No		reign Document imber ³	Country Code ²		Kind Code4	Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Tn

NON-PATENT LITERATURE DOCUMENTS							Remove		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
	ľ	11-00031			1333-03-00	OLGA ENTER ETD			
	1	11-86031	JP		1999-03-30	SEGA ENTERP LTD			П

If you wish to due additional if dreight Patent Document citation millionnation please click the Add button								
		NON-PATENT LITERATURE DOCUMENTS Remove						
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher city, and/or country where publisher city.	T5					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09902224		
Filing Date		2001-07-10		
First Named Inventor Shiny		a TSUKIZAKI		
Art Unit		2628		
Examiner Name Jacint		ta M. CRAWFORD		
Attorney Docket Number		SCED 18,553		

	1	Rejection of the Application dated November 8, 2011, from corresponding Japanese Application Number 2010-277041.	×					
	2	AKIRA YAMASHTA, et al "Biohazard 3 Last Escape Official Guide Book Dasshutsu Sukou Hen First Edition" Capcom Co., Ltd., October 6, 1999, pp. 16-21.						
If you wish to add additional non-patent literature document citation information please click the Add button Add								

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Knd Codes of USPTO Patent Documents at www.USPTO.500 or MPEP 801.54. Exter office that issued the document, by the two-letter code (WIPO Standard ST 3). "For Japanese patent documents, the reduction of the paint of the reging of the dispacer must precede the senial number of the patent document. Expendit pages patent senial to the reducent senior WIPO Standard ST.16 (posted). "Applicant to by place a reduction with with the patent senior sen

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09902224
Filing Date		2001-07-10
First Named Inventor	Shiny	a TSUKIZAKI
Art Unit		2628
Examiner Name Jacint		ta M. CRAWFORD
Attorney Docket Number		SCED 18.553

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
X	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement, See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

David Schalk

☐ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.			
Signature	/David Schalk/	Date (YYYY-MM-DD)	2011-12-30

Registration Number

60527

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Comments of the Comment of t

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicided to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested process and or examine your submission related to a patient application or patient. If you do not furnish the requested remaining the processing of the patient processing or the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.